Home > Media Centre > Press Releases
Press releases
AM-PHARMA PROVIDES BUSINESS UPDATE AND OUTCOME OF PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 REVIVAL STUDY
Phase 3 REVIVAL study stopped per recommendation of data…
AM-PHARMA ANNOUNCES PUBLICATION OF IN VIVO ACUTE KIDNEY INJURY STUDY DEMONSTRATING ILOFOTASE ALFA’S DUAL PROTECTIVE MECHANISM
Study shows ilofotase alfa protects against ischemia-reperfusion…
AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference
Utrecht, The Netherlands, June 6, 2022 – AM-Pharma B.V., an…
400 PATIENTS HAVE BEEN ENROLLED IN AM-PHARMA’s PIVOTAL PHASE 3 STUDY OF ILOFOTASE ALFA FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY
Decision from the first pre-specified futility analysis at…
AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect
Utrecht, The Netherlands, March 22, 2022 – AM-Pharma B.V.,…